Don Yuen1, Sammy Grimaldo1, Roberto Sessa1, Tatiana Ecoiffier1, Tan Truong2, Eric Huang1, Michael Bernas3, Sarah Daley3, Marlys Witte3, Lu Chen2. 1. Center for Eye Disease and Development, Program in Vision Science and School of Optometry, University of California, Berkeley, Berkeley, California, United States. 2. Center for Eye Disease and Development, Program in Vision Science and School of Optometry, University of California, Berkeley, Berkeley, California, United States Graduate Group in Vision Science, University of California, Berkeley, Berkeley, California, United States. 3. Department of Surgery, School of Medicine, University of Arizona, Tucson, Arizona, United States.
Abstract
PURPOSE: Lymphatic research has progressed rapidly in recent years. Lymphatic dysfunction has been found in myriad disorders from cancer metastasis to transplant rejection; however, effective treatment for lymphatic disorders is still limited. This study investigates the role of angiopoietin-2 (Ang-2) in corneal inflammatory lymphangiogenesis (LG) in vivo and in lymphatic endothelial cell (LEC) functions in vitro. METHODS: Standard suture placement model was used to study Ang-2 expression in inflamed cornea, and corneal LG and hemangiogenesis (HG) responses in Ang-2 knockout mice. Moreover, human LEC culture system was used to examine the effect of Ang-2 gene knockdown on LEC functions using small interfering RNAs (siRNAs). The effect of siRNA treatment on corneal LG was also assessed in vivo. RESULTS: Angiopoietin-2 was expressed on lymphatic vessels and macrophages in inflamed cornea. While corneal LG response was abolished in Ang-2 knockout mice, the HG response was also significantly suppressed with disorganized patterning. Moreover, anti-Ang-2 treatment inhibited LEC proliferation and capillary tube formation in vitro and corneal LG in vivo. CONCLUSIONS: Angiopoietin-2 is critically involved in lymphatic processes in vivo and in vitro. Further investigation of the Ang-2 pathway may provide novel insights and therapeutic strategies for lymphatic-related disorders, which occur both inside and outside the eye. Copyright 2014 The Association for Research in Vision and Ophthalmology, Inc.
PURPOSE: Lymphatic research has progressed rapidly in recent years. Lymphatic dysfunction has been found in myriad disorders from cancer metastasis to transplant rejection; however, effective treatment for lymphatic disorders is still limited. This study investigates the role of angiopoietin-2 (Ang-2) in corneal inflammatory lymphangiogenesis (LG) in vivo and in lymphatic endothelial cell (LEC) functions in vitro. METHODS: Standard suture placement model was used to study Ang-2 expression in inflamed cornea, and corneal LG and hemangiogenesis (HG) responses in Ang-2 knockout mice. Moreover, human LEC culture system was used to examine the effect of Ang-2 gene knockdown on LEC functions using small interfering RNAs (siRNAs). The effect of siRNA treatment on corneal LG was also assessed in vivo. RESULTS:Angiopoietin-2 was expressed on lymphatic vessels and macrophages in inflamed cornea. While corneal LG response was abolished in Ang-2 knockout mice, the HG response was also significantly suppressed with disorganized patterning. Moreover, anti-Ang-2 treatment inhibited LEC proliferation and capillary tube formation in vitro and corneal LG in vivo. CONCLUSIONS:Angiopoietin-2 is critically involved in lymphatic processes in vivo and in vitro. Further investigation of the Ang-2 pathway may provide novel insights and therapeutic strategies for lymphatic-related disorders, which occur both inside and outside the eye. Copyright 2014 The Association for Research in Vision and Ophthalmology, Inc.
Authors: Hans J Geissler; Alexey Dashkevich; Uwe M Fischer; Jochen W U Fries; Ferdinand Kuhn-Régnier; Klaus Addicks; Uwe Mehlhorn; Wilhelm Bloch Journal: Eur J Cardiothorac Surg Date: 2006-01-24 Impact factor: 4.191
Authors: K Teichert-Kuliszewska; P C Maisonpierre; N Jones; A I Campbell; Z Master; M P Bendeck; K Alitalo; D J Dumont; G D Yancopoulos; D J Stewart Journal: Cardiovasc Res Date: 2001-02-16 Impact factor: 10.787
Authors: Tina Dietrich; Jasmine Onderka; Felix Bock; Friedrich E Kruse; Dörte Vossmeyer; Roland Stragies; Grit Zahn; Claus Cursiefen Journal: Am J Pathol Date: 2007-07 Impact factor: 4.307
Authors: Michael Dellinger; Robert Hunter; Michael Bernas; Nicholas Gale; George Yancopoulos; Robert Erickson; Marlys Witte Journal: Dev Biol Date: 2008-04-27 Impact factor: 3.582
Authors: Gyeong Jin Kang; Tan Truong; Eric Huang; Valerie Su; Shaokui Ge; Lu Chen Journal: Invest Ophthalmol Vis Sci Date: 2016-11-01 Impact factor: 4.799